404
Views
13
CrossRef citations to date
0
Altmetric
Report

The experience of financial toxicity among advanced melanoma patients treated with immunotherapy

, PhDORCID Icon, , MS, , MS, , MD, MPH, , MD, , MA, , MD, MBA & , MD show all
 

Abstract

Purpose

To measure financial toxicity and explore its association with quality of life (QOL) in an emerging population of survivors: advanced melanoma patients treated with immunotherapy.

Design

Cross-sectional survey and medical record review.

Sample

106 survivors (39% response). Median time since start of immunotherapy was 36.4 months (range: 14.2–133.9).

Methods

The Comprehensive Score for Financial Toxicity measured financial toxicity, and the EORTC-QLQ30 assessed QOL and functioning across five domains. Data were collected online, by phone, or in clinic.

Findings: Younger patients (<65 years) reported higher financial toxicity (p < .001) than older patients. Controlling for age, financial toxicity was correlated with QOL (p < .001), financial difficulties (p < .001), and EORTC-QLQ30 functioning subscales.

Conclusions

Given the demonstrated association between financial toxicity and QOL, our study highlights the importance of addressing financial toxicity, particularly among patients receiving high-cost treatments.

Implications for Psychosocial Providers: Providers should educate patients and their caregivers about cost-management techniques, link them with available resources, and provide psychosocial counseling to alleviate related distress.

Acknowledgement

The authors would like to thank Drs. Michael A. Postow, Jedd A. Wolchok, and Jun J. Mao for their contributions to the larger study from which these data were drawn.

Disclosure statement

The authors have no conflicts of interest.

Data availability

De-identified data that support the findings of this study are available on request from the corresponding author, BT. The data are not publicly available due to the privacy of research participants.

Additional information

Funding

This manuscript was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.